eXTReMe Tracker

Main Menu

Login Form

Related Links

New and Updated Clinical Ebola Vaccine Trials

Latest Ebola vaccine studies updated or received at ClinicalTrials.gov. Only open studies, recruiting or not yet recruiting, are shown found by a search using the keyword: "ebola"

  • Prophylaxis Vaccine Antibodies Ebola

    Mar 30, 2021 | 18:00 pm

    Condition:   Ebola Virus DiseaseInterventions:   Drug: ansuvimab;   Biological: ErveboSponsor:   ANRS, Emerging Infectious DiseasesNot yet recruiting

  • Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

    Nov 5, 2019 | 18:00 pm

    Condition:   Ebola Virus DiseaseIntervention:   Biological: Ad26.ZEBOV, MVA-BN-Filo vaccineSponsors:   London School of Hygiene and Tropical Medicine;   Epicentre;   Ministère de la Santé de la RDC;   Médecins Sans Frontières, France;   Coalition for Epidemic Preparedness Innovations;   Janssen Vaccines & Prevention B.V.;   Public Health EnglandUnknown status

  • Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

    Aug 1, 2019 | 18:00 pm

    Condition:   Ebola VirusIntervention:   Biological: cAd3-EBO S vaccineSponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   US Military HIV Research ProgramCompleted

  • Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

    Oct 25, 2018 | 18:00 pm

    Condition:   Ebola VirusInterventions:   Drug: ZMapp;   Drug: Remdesivir;   Drug: MAb114;   Drug: REGN-EB3Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)Completed

  • Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines

    May 4, 2017 | 18:00 pm

    Condition:   Ebola Virus DiseaseIntervention:   Biological: Previously exposed to Ebola vaccineSponsors:   University of Oxford;   University of GlasgowCompleted

  • PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response

    Apr 4, 2017 | 18:00 pm

    Condition:   Ebola Virus DiseaseIntervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)Completed

  • African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

    Jan 26, 2017 | 18:00 pm

    Condition:   EbolaInterventions:   Biological: V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine;   Other: SalineSponsors:   Cecile Tremblay;   Merck Sharp & Dohme LLC;   International Development Research Centre, Canada;   Dalhousie University;   Université de Montréal;   Coalition for Epidemic Preparedness InnovationsActive, not recruiting

  • Partnership for Research on Ebola VACcinations

    Aug 23, 2016 | 18:00 pm

    Condition:   Ebola Virus DiseaseInterventions:   Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boostSponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Partnership for Research on Ebola Virus in Liberia (PREVAIL);   Institut National de la Santé Et de la Recherche Médicale, France;   London School of Hygiene and Tropical Medicine;   European and Developing Countries Clinical Trials Partnership (EDCTP)Active, not recruiting

  • GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen

    Jun 29, 2016 | 18:00 pm

    Condition:   EbolaInterventions:   Drug: GS-5734;   Other: Placebo ComparatorSponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Gilead SciencesCompleted

  • Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

    Mar 24, 2016 | 17:00 pm

    Condition:   Ebola Virus DiseaseInterventions:   Biological: Ebola Vaccine - low dose;   Biological: Ebola Vaccine - mid dose;   Biological: Ebola Vaccine - high dose;   Biological: PlaceboSponsors:   Auro Vaccines LLC;   Accelovance;   United States Department of DefenseCompleted

  • A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

    Aug 27, 2015 | 18:00 pm

    Condition:   Ebola Virus DiseaseInterventions:   Biological: 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: placeboSponsors:   Jiangsu Province Centers for Disease Control and Prevention;   Beijing Institute of Biotechnology;   Tianjin Cansino Biotechnology IncCompleted

  • Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up

    May 1, 2015 | 18:00 pm

    Condition:   Ebola Virus DiseaseIntervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)Completed

  • STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)

    Mar 4, 2015 | 18:00 pm

    Condition:   Hemorrhagic Fever, EbolaIntervention:   Biological: rVSVΔG-ZEBOVSponsors:   Centers for Disease Control and Prevention;   University of Sierra Leone;   Ministry of Health and Sanitation, Sierra Leone;   Department of Health and Human Services;   eHealth AfricaCompleted

  • Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

    Feb 3, 2015 | 18:00 pm

    Condition:   Hemorrhagic Fever, EbolaInterventions:   Biological: cAd3-EBOZ;   Biological: cAd3-EBO;   Biological: MVA-EbolaZSponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   US Military HIV Research Program;   The Emmes Company, LLCCompleted

  • Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

    Jan 26, 2015 | 18:00 pm

    Condition:   Ebola VirusInterventions:   Biological: VSVG-ZEBOV;   Biological: ChAd3-EBO Z;   Biological: PlaceboSponsor:   National Institute of Allergy and Infectious Diseases (NIAID)Completed

  • Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea

    Jan 19, 2015 | 18:00 pm

    Condition:   Hemorrhagic Fever, EbolaIntervention:   Other: Convalescent PlasmaSponsors:   Institute of Tropical Medicine, Belgium;   National Blood Transfusion Centre (NBTC), Conakry, Guinea;   Gamal Abdel Nasser University of Conakry;   National Center for Training and Research of Maferinyah, Guinea;   Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;   University of Oxford;   University of Liverpool;   London School of Hygiene and Tropical Medicine;   Aix Marseille Université;   UBIVE, Institut Pasteur, Paris, France;   Institut National de la Santé Et de la Recherche Médicale, France;   Etablissement Français du Sang;   Belgian Red Cross;   Institut Pasteur, Dakar, Sénégal;   Médecins Sans Frontières, Belgium;   World Health Organization;   International Severe Acute Respiratory and Emerging Infection ConsortiumCompleted

  • A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

    Dec 25, 2014 | 18:00 pm

    Condition:   Ebola Virus DiseaseInterventions:   Biological: Low dose Ebola Zaire vaccine (Ad5-EBOV);   Biological: High dose Ebola Zaire vaccine (Ad5-EBOV);   Biological: placebo (one dose);   Biological: placebo (two doses)Sponsors:   Jiangsu Province Centers for Disease Control and Prevention;   Beijing Institute of Biotechnology;   Tianjin Cansino Biotechnology IncCompleted

  • Phase 1 Trial of Ebola Vaccine in Mali

    Oct 17, 2014 | 18:00 pm

    Conditions:   Ebola Virus Disease;   Hemorrhagic FeverInterventions:   Biological: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z;   Biological: Booster-MVA-BN® Filo or saline placeboSponsors:   University of Maryland, Baltimore;   Wellcome Trust;   National Institute of Allergy and Infectious Diseases (NIAID);   Leidos Biomedical Research, Inc.Completed

  • A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

    Sep 16, 2014 | 18:00 pm

    Conditions:   Ebola;   Ebola ZaireInterventions:   Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® FiloSponsors:   University of Oxford;   Wellcome Trust;   National Institute of Allergy and Infectious Diseases (NIAID)Completed

  • Evaluating an Ebola and a Marburg Vaccine in Uganda

    Oct 19, 2009 | 18:00 pm

    Conditions:   Ebola Virus Disease;   Marburg Virus DiseaseInterventions:   Biological: Ebola vaccine;   Biological: Marburg vaccine;   Other: Placebo injectionSponsor:   National Institute of Allergy and Infectious Diseases (NIAID)Completed



Ebola News